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Abstract: BACKGROUND: Hospitalizations for severe infections associated with substance use 
disorder (SUD) are increasing. People with SUD often remain hospitalized for many weeks 
instead of completing intravenous antibiotics at home; often, they are denied skilled nursing 
facility admission. Residential SUD treatment facilities are not equipped to administer 
intravenous antibiotics. We developed a medically enhanced residential treatment (MERT) 
model integrating residential SUD treatment and long-term IV antibiotics as part of a broader 
hospital-based addiction medicine service. MERT had low recruitment and retention, and ended 
after six months. The goal of this study was to describe the feasibility and acceptability of 
MERT, to understand implementation factors, and explore lessons learned.  
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METHODS: We conducted a mixed-methods evaluation. We included all potentially eligible 
MERT patients, defined by those needing ≥2 weeks of intravenous antibiotics discharged from 
February 1 to August 1, 2016. We used chart review to identify diagnoses, antibiotic treatment 
location, and number of recommended and actual IV antibiotic-days completed. We audio-
recorded and transcribed key informant interviews with patients and staff. We conducted an 
ethnographic analysis of interview transcripts and implementation field notes.  
 
RESULTS: Of the 45 patients needing long-term intravenous antibiotics, 18 were ineligible and 
20 declined MERT. 7 enrolled in MERT and three completed their recommended intravenous 
antibiotic course. MERT recruitment barriers included patient ambivalence towards residential 
treatment, wanting to prioritize physical health needs, and fears of untreated pain in residential. 
MERT retention barriers included high demands of residential treatment, restrictive practices due 
to PICC lines, and perceptions by staff and other residents that MERT patients “stood out” as 
“different.” Despite the challenges, key informants felt MERT was a positive construct.  
 
CONCLUSIONS: Though MERT had many possible advantages; it proved more challenging to 
implement than anticipated. Our lessons may be applicable to future models integrating post-
hospital intravenous antibiotics and SUD care. 
 
 
Introduction: 
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United States hospitalizations for severe infections such as endocarditis and osteomyelitis 
among people with substance use disorder (SUD) have doubled in the last decade.
1
 Treatment for 
such infections typically requires six to eight weeks of intravenous (IV) antibiotics, and may 
require heart-valve surgery or other invasive procedures.  
Many people can complete a prolonged course of IV antibiotics at home or in a post-
acute care skilled nursing facility (SNF). However, people with SUD are often deemed unsafe to 
discharge home with IV antibiotics because of social risks such as homelessness or continued 
drug use; and often, they are denied admission to post-acute care facilities.
2, 3
 Thus, many with 
SUD have hospitalizations that extend weeks or months to complete an antibiotic course.
4
 
Despite this, outcomes remain poor. People with SUD are more likely to be denied valve 
surgery, leave the hospital against medical advice, and die.
2, 5
 Hospital systems commonly do not 
provide SUD treatment, yet hospitalization can be a reachable moment to initiate and coordinate 
SUD treatment.
6
 
Just as hospitals are not equipped to provide SUD treatment, SUD treatment settings are 
not equipped to provide complex medical care.
4
 Residential addiction treatment settings are not 
routinely staffed by physicians or nurses and do not have expertise to provide wound care, 
intravenous antibiotics, or other physical health care.  
Studies examining alternative care models to address combined antibiotic and SUD needs 
are limited. One single-site, retrospective study retrospectively reviewed 205 medical charts of 
patients discharged to a residential addiction treatment setting where they received IV antibiotics 
between 2006 and 2011.
7
 Seventy-three percent of patients completed their course of antibiotics, 
with sizable savings in hospital days and costs. However, this study did not report patient 
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characteristics, preferences, or outcomes of those who did not enter this care model. This study 
did not describe patient or SUD treatment provider experiences, nor did it describe 
implementation experience.  
We developed and implemented a medically enhanced residential treatment (MERT) 
model as part of a broader hospital-based addiction medicine service
4
. MERT aimed to deliver 
IV antibiotics in residential addiction treatment for patients with SUD who were medically stable 
for discharge but needed ongoing long-term IV antibiotics. While the overall hospital-based 
addiction medicine service thrived, MERT had low recruitment and retention. Ultimately we 
decided to end MERT after six months. The goal of this study was to describe the feasibility and 
acceptability of MERT; and, given limited acceptability, to understand implementation barriers 
and explore lessons learned. 
Methods 
 
MERT was part of a multicomponent hospital-based addiction medicine intervention, the 
Improving Addiction Care Team (IMPACT) that includes care from addiction medicine 
physicians, social workers, and peers with lived experience in recovery. All MERT patients 
received care from IMPACT. Earlier studies describe IMPACT rationale and design.
4, 6
 Our 
institutional review board approved all study procedures.  
Setting: 
MERT was a collaboration between a university hospital, a community-based SUD 
treatment agency, and a specialty infusion pharmacy.  The hospital is a 522-bed urban academic 
medical center in Oregon.  During the study period, the hospital had an Outpatient Parenteral 
Antibiotic Therapy (OPAT) program. OPAT managed all patients leaving the hospital with 
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intravenous antibiotics and included direct medical care from infectious disease providers and 
intensive case management. OPAT monitored antibiotic complications, completion, and follow 
up needs (e.g. laboratory tests).  
The community-based SUD treatment agency (CODA) is a non-profit agency that 
provides outpatient treatment, medication for addiction treatment (MAT) (e.g. methadone, 
buprenorphine), medically supervised withdrawal, and residential treatment. The residential site 
that housed MERT includes 42 men‟s beds and 22 women‟s beds. Prior to MERT, residential 
treatment did not have nursing or medical staff. Residential treatment enforced the traditional 30-
day “blackout period” during which unsupervised visitors, personal mobile devices, and internet 
use is prohibited. CODA agreed to prioritize MERT patients waiting for a residential bed.  
The specialty infusion pharmacy is a private company whose nurses deliver home 
infusion services including antibiotic administration and real-time support in the case of 
complications (e.g. catheter malfunction). The company had not previously worked in residential 
treatment.  
Intervention Description:  
MERT was located within a traditional residential addiction treatment setting where 
residents were expected to participate in 20 hours of groups and 1 hour of individual therapy 
each week. Home infusion nurses administered daily antibiotic infusions and performed weekly 
dressing changes of peripherally inserted central catheters (PICC).  The MERT registered nurse 
(RN) did an in-person handoff with hospital nurses and IMPACT prior to discharge and 
accompanied patients directly from hospital to MERT. All team members were informed of the 
workflow (appendix). The MERT RN coordinated post-hospital medical care and attended all 
off-campus follow-up visits. MERT patients and MERT RN participated in weekly telemedicine 
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rounds with the hospital-based infectious disease team. We made establishing with a primary 
care provider (and in some cases a mental health provider) a requirement for MERT.   
Hospital-based infectious disease teams referred all patients needing long-term IV 
antibiotics (defined as ≥2 weeks) with SUD to IMPACT, and all were considered for MERT. 
MERT patients had to agree to enroll in residential SUD treatment; meet residential treatment 
criteria based on addiction severity (ASAM level of care 3.1-3.5); perform activities of daily 
living independently; require no more than once daily antibiotic infusions; limit prescription 
opioids for pain to no more than three times daily with a taper plan; and, have insurance that 
would cover residential addiction treatment at CODA.  
During hospitalization, an IMPACT social worker assessed all potential MERT patients‟ 
interest in MERT and worked to enhance treatment motivation. The MERT registered nurse 
(RN) visited all interested patients in their hospital room to discuss treatment expectations and to 
review the anticipated residential care plan. 
 
Intervention Financing 
MERT was funded by Oregon Health & Science University and a Medicaid coordinated care 
organization.
4
 We estimated that MERT would serve approximately 30 patients/year and 3 
individuals at any time.  We contracted to pay infusion pharmacy for 6-days/ week of infusion 
costs (insurance covers once-weekly home infusion) and we supported additional CODA 
residential staffing that included 0.1 physician, 0.7 RN, 0.2 residential manager time.
4
 The 
hospital infectious disease OPAT team provided in-kind support for 30 minutes/week telehealth 
rounds.  
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Implementation Process 
We constructed stakeholder partnerships that were integral to the design,
4
 implementation, and 
evaluation phases of MERT. We held on-site planning visits at the hospital and residential 
settings that included all partners. During implementation we held biweekly meetings with 
IMPACT clinicians and residential staff to identify potentially eligible patients and discuss 
barriers and potential solutions. As we identified barriers (e.g. residential staff discomfort with 
wound care), we provided staff trainings to address them. We also modified the intervention to 
better serve complex patient-care needs. For example, IMPACT helped patients change 
insurance and tailored antibiotics to once daily regimens if possible. In one case, IMPACT 
worked with federal marshals and local parole officers to squash warrants to avoid incarceration 
and permit entrance into residential. We held quarterly meetings with all partners across 
organizations and roles (e.g. clinical care, implementation, evaluation). 
 
Evaluation 
We conducted a mixed-methods evaluation of MERT implementation. We employed a 
sequential explanatory research design,
8
 using qualitative data to gain a deeper understanding of 
quantitative results. Our evaluation included all IMPACT patients who were potentially eligible 
for MERT, as defined by those needing at least 2 weeks of IV antibiotics who were discharged 
between February 1 and August 1, 2016. 
 
Quantitative data collection and analysis 
We collected demographic data including age, gender, race, and insurance from hospital 
administrative data. We collected data on housing and substance use from an IMPACT study 
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registry. We performed chart review to identify primary hospital diagnosis, antibiotic treatment 
location (MERT, hospital, SNF, home); number of recommended IV antibiotic days and actual 
IV antibiotic days completed. We used a study registry to identify reasons people did not attempt 
MERT and confirmed reasons by chart review. 
We defined antibiotic completion if the actual number of treatment days was greater than 
or equal to the number of days of IV antibiotics recommended. We considered salvage therapy if 
patients transitioned to oral therapy prior to completing the recommended IV antibiotic course. 
We considered therapy incomplete if participants completed neither IV antibiotics nor salvage 
therapy.  
 
Qualitative data collection and analysis 
We performed semi-structured interviews with key informants to understand barriers, 
facilitators, and effects of MERT. We also reviewed MERT development and implementation 
field notes. We used purposive sampling to identify six key informants including:  an IMPACT 
social worker, the CODA-IMPACT liaison, an IMPACT physician, CODA‟s executive director, 
the residential manager, and the MERT RN. We conducted qualitative interviews with four 
patients who needed long-term IV antibiotics, two who went to MERT and two who did not. 
Patient participants completed interviews approximately 30 days after hospital discharge.  
All interviews were audio recorded and transcribed.  We conducted an ethnographic 
analysis of interview transcripts and field notes, focusing on insights that may best describe the 
phenomenon and inform future interventions.
9
 Two authors independently coded all transcripts 
and reconciled codes by consensus. We reviewed preliminary findings with key informants as a 
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form of member checking. The full team, including experts in qualitative methods and SUD, 
finalized results. 
 
Results: 
 
Recruitment 
During the study period there were 45 patients needing long-term IV antibiotics (Table 
1). Eighteen were ineligible, 20 declined, and 7 discharged to MERT. Patients were ineligible for 
various reasons, including active warrants, insurance, need for multiple daily antibiotic infusions, 
inability to perform independent activities of daily living, ongoing physical rehabilitation needs. 
Most patients who declined were unwilling to commit to residential treatment (Figure 1).  
Key informants repeatedly described that MERT was “hard to sell.” Many patients 
expressed ambivalence towards residential treatment, especially after acute hospitalization. As an 
IMPACT physician recalled:  
“Many patients would say, I want to address my medical issues now and then I‟ll address 
my addiction issues after… we heard [that] over and over.”  
For some, ambivalence was exacerbated by a changing medical plan and discharge date, which 
made coordinating a residential bed difficult. Facing so many “what-if‟s,” some patients‟ 
motivation waned.  Some had concerns about the demands of a highly structured treatment 
program and others did not want to be separated from friends, family, pets and home.  
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Patients also worried about getting adequate pain control in residential, and feared that by 
agreeing to MERT, they would have to forgo pain medication. As one patient who attended 
MERT recalled,  
“Having my surgery on my back, and then 10 days later, “let‟s stick you in a treatment 
facility”... where I had to walk around and take classes…. I was initially worried about 
my physical ability to do so…. I was gonna be in a significant amount of pain… [and] the 
transition from my oxycodone and dilaudid to methadone concerned me at first…” 
 
 
Retention: 
Of the 7 patients who went to MERT, 4 left against medical advice (AMA) before completing 
the recommended antibiotic course. Key informants highlighted “culture shock” with the 
transition from the hospital to MERT. They repeatedly described that the 20-hours of per week 
of groups was challenging for MERT patients. As MERT‟s residential manager described: 
“Patients were in the hospital for long periods of time, so there was a lot of downtime… 
and once they got into treatment… you‟re talking about a pretty strict schedule. They 
were expected to get up at a certain time, your meal is at a certain time, you have to go 
take your medications. And you have to do that as opposed to a nurse getting everything 
to you, and I can watch TV and sleep in… it is a different mindset that you really had to 
be ready for.” 
In some cases, staff perceived MERT patients‟ lesser participation in residential as disruptive to 
the treatment environment.  
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 Attitudes of residential staff towards medical complexity may have influenced retention. 
An IMPACT social worker recalled his sense that, “[some] counselors were refusing to work 
with the MERT patients… because of the medical complexities. Not because they didn‟t like 
them or want them, but because they were hard, difficult, complex people.” Residential staff 
often felt “on edge” because patients had PICC lines, which they feared were “a direct portal 
right to their heart, they could overdose at any moment.” These fears increased staffs‟ vigilance 
and led them to implement added restrictions for MERT patients. As the residential program 
manager described: 
“[Staff] couldn‟t let them out into the community. We couldn‟t let them … be outside and 
do exercise walks, or those kinds of things because it was really high risk… It‟s hard to 
watch your peers be able to come and go in the community, and you not be able to 
participate.” 
These restrictions were repeatedly identified as a key barrier to MERT completion rates, and led 
to MERT patient dissatisfaction. As one patient described, MERT felt “like jail” and he felt 
“completely lied to.” IMPACT leadership, inpatient addiction medicine, and infectious disease 
teams only learned about these restrictions after MERT had ended.  
 Finally, key informants described that MERT patients were often “isolated” from other 
residents. They speculated that this resulted partly from fear of contagion given visible wounds, 
stigma towards those with medical illness, resentment of “special treatment” that allowed MERT 
patients to be accompanied to off-campus medical appointments, and use of MAT that was 
uncommon amongst other residents. The IMPACT-CODA liaison described: 
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“A lot of the patients at residential sort of pushed against that. The IMPACT patients, 
like, you just sort of got here. And you took someone else‟s bed… you don‟t have to go 
to groups because you have to go to an appointment. Or just like, you get specialized 
care. And that just really rubbed against patients the wrong way.” 
 
Potential Utility: 
Though overall IV antibiotic completion was low (44%), a majority of participants either 
completed ≥80% of recommended IV antibiotics (64%) and/or completed salvage therapy (24%).  
A combination of discharge to MERT, SNF, or home allowed for 384 days of IV antibiotics 
delivered outside of the hospital. Though numbers are too small for statistical comparisons, 
information about antibiotic completion rates and out-of-hospital IV antibiotic days are presented 
in table 2. 
 Despite the challenges, nearly all respondents felt that the MERT construct was positive 
and worth pursuing again. Respondents felt that the patients who completed MERT benefitted 
greatly. As the MERT RN emphasized, “there wasn‟t anything else like it … the people it did 
impact, it profoundly impacted.” Respondents praised MERT‟s success with highly motivated 
patients, particularly those with external motivating factors such as reuniting with their family or 
avoiding legal issues. 
This sentiment was echoed by one patient who completed the program: 
“I‟m so grateful for this program cause instead of being in the hospital… and just 
basically doing nothing except getting your injection every day… out here, not only do I 
get to address my addiction, but I have the opportunity to go to NA meetings or AA 
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meetings… Initially, I probably went into the program saying „hey, well I‟ll just wait for 
my antibiotics to be done and then I can leave.‟ Well, no. After a couple a days, I‟m like 
that‟s not what I really want. I want to finish this program. I need to do things 
differently.” 
Finally, independent of MERT‟s explicit goal to facilitate access to IV antibiotics, 
respondents noted that having an on-site nursing increased residential treatment‟s ability to care 
for more medically complex patients, including expanded use of MAT in residential (which he 
estimated “almost doubled”) and more staff familiarity caring for patients with wounds, diabetes, 
or other common medical problems.  
MERT alternatives 
The majority of participants did not go to MERT, and instead went to SNF or stayed in the 
hospital. However, these settings had different limitations. SNFs commonly resisted accepting 
patients with SUD or homelessness, and SNFs felt they had limited ability to administer 
methadone due to their interpretation of federal regulations. SNF staff typically had no addiction 
training and the SNF environment was largely unmonitored with reports of active drug use on 
premises. Many SNF patients also felt ostracized due to their SUD.  Hospital was a more 
controlled environment; however prolonged admissions are extremely costly. Furthermore, even 
with IMPACT, hospital care had limited ability to prepare patients for post-hospital trigger-rich 
environments. As one staff participant described: “Just leaving the hospital… as soon as you 
drive down Burnside [street], you‟re in a more trigger rich environment. And you begin to lose 
people.” 
Discussion: 
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Though MERT had many possible theoretical advantages, it proved more challenging to 
implement than anticipated. Recruitment barriers included patient‟s medical complexity, patient 
concerns about physical health and pain, and ambivalence towards residential treatment. 
Retention barriers included high demands of residential treatment, restrictive residential practices 
due to PICC lines, and the perception that MERT patients “stood out” as “different.” Despite the 
challenges, the majority of patients completed IV antibiotic or salvage therapy and MERT saved 
a modest number of hospital days. Most providers felt that there was some value in the care 
model that should inform future trial.  
Our experience builds on existing research in several important ways.  An earlier study 
by Jewell and colleagues
7
 describes a program that continued successfully for 6 years with 
higher retention rates (73% completing IV-antibiotics versus our 43%) and relatively low 
patient-volumes (<3 patients/ month). While an important precedent, Jewell and colleagues do 
not describe recruitment – describing experiences only of those who went to their program – nor 
do they elaborate on patient/staff experience. Our finding that many patients did not want 
residential treatment serves as an important caution that programs such as Jewell‟s may not be a 
solution for many patients and health systems.  
Differences in the Jewell program and ours highlight potentially important differences in 
settings and implementation strategies. Higher retention rates in Jewell could be related to pre-
existing on-site nursing staff in residential treatment, which may have increased residential 
staffs‟ comfort managing medical problems and mitigated the perception that patients with 
medical illness were „different.‟ Also, Jewell included a fixed monthly rate to reserve residential 
bed-capacity and an additional payment for each day a bed was occupied. In MERT, additional 
 
 
 
 
 
 
 
 
 
17 
 
staff were financed up-front and were an expense even if there were no MERT patients. A daily 
rate may have incentivized residential staff to retain patients in residential and reduced financial 
strain on the hospital in that the hospital would pay for a resource proportional to its use. 
Importantly, the Jewell program was implemented in a more integrated system. The effort 
necessary to initiate and maintain MERT in non-integrated systems may be substantially greater. 
Finally, the challenges we had with patients who discharged to SNF echo others‟ description of 
post-acute barriers for patients with SUD in SNF.
10
  
Our experience designing and implementing IMPACT supports that hospitalization is a 
reachable moment to engage patients and initiate addiction care.
6
 However, residential treatment 
may represent a higher bar, particularly given the intensive residential addiction treatment 
demands; the restrictions on visitors, cell phones and internet; and limitations on opioid pain 
medications. Fear of unmet pain needs is a common concern amongst hospitalized patients with 
SUD.
11
 Others have questioned whether such restrictions are necessary.
12
 Our experience 
suggests that these barriers may dissuade patients from entering or completing residential 
treatment.  
Our study has several key limitations. First, it took place at a single-academic medical 
center and single residential treatment program in Oregon, limiting the generalizability of our 
findings. Our six-month experience included a small number of participants. Though we did not 
have large enough numbers to compare outcomes across various settings, we present outcomes 
for patients who remained inpatient or discharged to MERT, SNF, and home. Our qualitative 
evaluation focused on MERT and was not designed to thoroughly explore other treatment 
settings, a topic of future investigation. Despite these limitations, our experience may be 
important to others trying to improve care for people requiring intravenous antibiotics with SUD.  
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Our experience has several key implications. The finding that hospitalized patients 
declined residential treatment is important and suggests the need for flexible, patient-centered 
post-acute care models that can engage patients who range from pre-contemplative to action 
stages of change. Findings that residential staff felt “on edge” and that patients with medical 
problems “stood out” in residential treatment underscore the need for training to support 
integrated physical and behavioral health models. Though we hired an on-site MERT nurse and 
part-time physician who led some training, we underestimated the time and support residential 
staff would need to feel comfortable working with recently hospitalized patients. Future efforts 
might benefit from more dedicated time and resources for staff education, including all-staff 
trainings about PICC lines, MAT, and pain. Finally, though MERT was developed based on a 
patient needs assessment and broad stakeholder input
4
, our experience raises the question of 
whether a more iterative design process that included ongoing feedback from adults with SUD 
and residential staff may have led to a more successful intervention. Our experience highlights 
the need to anticipate and adapt to barriers relating to patients with SUD (e.g. concerns about 
pain management), organizations (e.g. changing hospital discharge dates and residential bed 
capacity), and the program itself (e.g. staff attitudes). 
Despite our challenges, we believe there may still be benefit to creating options for 
patients to receive long-term IV antibiotics outside of the hospital. Even with low recruitment 
and retention, we saved over 300 hospital days with the majority of patients completing IV 
antibiotics or salvage therapy. Our findings underscore the need for more flexible, patient-
centered treatment models. Future programs might integrate addiction supports into post-acute 
medical care. Given high prevalence of homelessness among people with SUD, a model that 
warrants exploration is to integrate IV antibiotics and substance use treatment in medical respite 
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facilities.
13
 Medical respite – which is proliferating across the US - provides post-acute medical 
care for homeless persons who are too ill to recover from a physical illness on the streets.
14
 
Medical respite could be staffed with nurses to provide infusions and case management; 
physicians to prescribe opioid agonist therapy; and, recovery supports, including peers in 
recovery. Alternatively, studies might explore modifying physical health treatment plans to 
accommodate patients‟ behavioral health needs, for example, exploring off-label once weekly 
antibiotic infusions for patients who decline SNF or threaten to leave the hospital AMA. 
Future implementation research should explore alternative models of integrated treatment 
for patients with SUD requiring long-term intravenous antibiotics. It is unlikely that a single 
solution will emerge, especially given variations in settings and resources across communities. 
However, the lessons of our experience, including patient ambivalence towards residential 
treatment and the challenges of delivering physical healthcare in a residential addiction setting, 
are likely to be applicable in future models.  
Appendix 
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Figure. Participant flow diagram. 
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Table 1. Demographics of patients needing IV antibiotics and SUD treatment, comparing MERT and non-MERT 
individuals by antibiotic treatment location 
 All  Hospital MERT SNF Home 
 (n=45) (n=24) (n=7) (n=11) (n=3) 
Mean age in years 
(range) 
39 (21-69) 37 (21-69) 38 (28-57) 43 (25-55) 36 (27-46) 
Female Gender n 
(%) 
20 (44%) 12 (46%) 2 (29%) 4 (36%) 2 (67%) 
Non-Hispanic 
White n (%) 
38 (84%) 20 (83%) 6 (86%) 10 (91%) 2 (67%) 
Any Insurance (%) 45 (100%)     
     Oregon 
Medicaid 
33 (73%) 19 (79%) 4 (57%) 8 (73%) 2 (67%) 
Insecure housing n 
(%) 
23 (51%) 17 (71%) 2 (29%) 3 (27%) 1 (33%) 
Substance Use 
Disorder (%)*  
     
     Opioid  37 (82%) 23 (96%) 7 (100%) 5 (45%) 2 (67%) 
     
Methamphetamine  
27 (60%) 17 (71%) 2 (29%) 7 (64%) 1 (33%) 
     Cocaine  5 (11%) 3 (16%) 1 (14%) 0 1 (33%) 
     Alcohol  5 (11%) 2 (8%) 0 3 (27%) 0 
     Benzodiazepine  3 (7%) 0 2 (29%) 1 (9%) 0 
Any Severe SUD 
(%)*  
38 (84%) 23 (96%) 6 (86%) 8 (73%) 1(33%) 
Polysubstance use 
(%) 
28 (62%) 18 (75%) 5 (71%) 4 (36%) 1 (33%) 
Infection site      
Endocarditis 16 (36%) 11 (46%) 1 (14%) 4 (36%) 0 
Osteomyelitis 14 (31%) 6 (25%) 3 (43%) 4 (36%) 1 (33%) 
Bacteremia 9 (20%) 6 (25%) 0 1 (9%) 2 (67%) 
Other 6 (13%) 1 (4%) 3 (43%) 2 (18%) 0 
 
*Defined by Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM-5) criteria as assessed by 
IMPACT clinicians 
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Table 2. Antibiotic completion rates and out-of-hospital IV antibiotic days by planned antibiotic treatment 
location* 
 All 
(n=45) 
Hospital 
(n=24) 
MERT 
(n=7) 
SNF 
(n=11) 
Home 
(n=3) 
Completed recommended IV 
antibiotic course, % (n) 
44% (20) 42% (11) 43% (3) 64% (7) 33% (1) 
 
Completed at least 80% of 
recommended IV antibiotic course, 
% (n) 
 
64% (29) 
 
67% (16) 
 
43% (3) 
 
73% (8) 
 
67% (2) 
 
Salvage therapy with oral 
antibiotics, % (n)** 
 
24% (11) 
 
21% (5) 
 
29% (2) 
 
18% (2) 
 
67% (2) 
 
Total out-of-hospital IV antibiotic 
days 
 
384 
 
0 
 
101 
 
226 
 
57 
 
*All participants initiated their course of IV antibiotics in the hospital. This table describes the intended location for 
completion of IV antibiotic treatment.  
**Salvage therapy includes those who were transitioned from IV to oral antibiotics  
 
 
 
 
 
 
 
 
 
 
 
 
